KFDA instructed for Gleevec to be properly administered.

Published: 2001-09-20 06:56:00

Updated: 2001-09-20 06:56:00

The KFDA instructed the medical, hospital and pharmacist associations to administer Gleevec, a therapeutic agent for a chronic myeloid leukemia according to the approved indications and efficacies, because its use recently exploited to other cancers, thus causing its abuse and misuse.

Gleevec shall be indicated only for the acute and chronic myeloid leukemia according to Norvatis Korea, and...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.